EA201100155A1 - ПРИМЕНЕНИЕ 2-(1-ГИДРОКСИПЕНТИЛ)БЕНЗОАТА КАЛИЯ (dI-PHPB) ДЛЯ ПРЕДУПРЕЖДЕНИЯ И ЛЕЧЕНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА - Google Patents

ПРИМЕНЕНИЕ 2-(1-ГИДРОКСИПЕНТИЛ)БЕНЗОАТА КАЛИЯ (dI-PHPB) ДЛЯ ПРЕДУПРЕЖДЕНИЯ И ЛЕЧЕНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА

Info

Publication number
EA201100155A1
EA201100155A1 EA201100155A EA201100155A EA201100155A1 EA 201100155 A1 EA201100155 A1 EA 201100155A1 EA 201100155 A EA201100155 A EA 201100155A EA 201100155 A EA201100155 A EA 201100155A EA 201100155 A1 EA201100155 A1 EA 201100155A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prevention
treatment
hydroxypenthyl
allzheimer
phpb
Prior art date
Application number
EA201100155A
Other languages
English (en)
Other versions
EA022309B1 (ru
Inventor
Сяолян Ван
Ванхун Чжао
Цзинхуа Ян
Лиин Ван
Цзян Ли
Шаофэн Сюэ
Нань Фэн
Шипин Ма
Original Assignee
Инститьют Оф Мэтэрия Медика, Чайниз Экэдеми Оф Медикл Сайнсиз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инститьют Оф Мэтэрия Медика, Чайниз Экэдеми Оф Медикл Сайнсиз filed Critical Инститьют Оф Мэтэрия Медика, Чайниз Экэдеми Оф Медикл Сайнсиз
Publication of EA201100155A1 publication Critical patent/EA201100155A1/ru
Publication of EA022309B1 publication Critical patent/EA022309B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к применению 2-(1-гидроксипентил)бензоата калия для получения лекарственных средств для предупреждения, ослабления и лечения старческого слабоумия или его симптомов, и для уменьшения повреждения, вызванного окислительным стрессом, улучшения функции холинергических нейронов, защиты нейронов и повышения уровня нейротрофического фактора головного мозга. Изобретение также раскрывает фармацевтические композиции, содержащие 2-(1-гидроксипентил)бензоат калия в профилактически или терапевтически эффективной дозе, и, при необходимости, фармацевтически приемлемый носитель и/или разбавитель.
EA201100155A 2008-07-08 2008-07-08 ПРИМЕНЕНИЕ 2-(1-ГИДРОКСИПЕНТИЛ)БЕНЗОАТ КАЛИЯ (dl-PHPB) ДЛЯ ПРЕДУПРЕЖДЕНИЯ И ЛЕЧЕНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА EA022309B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2008/071588 WO2010003287A1 (zh) 2008-07-08 2008-07-08 2-(α-羟基戊基)苯甲酸钾预防和\或治疗老年痴呆的用途

Publications (2)

Publication Number Publication Date
EA201100155A1 true EA201100155A1 (ru) 2011-06-30
EA022309B1 EA022309B1 (ru) 2015-12-30

Family

ID=41506655

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100155A EA022309B1 (ru) 2008-07-08 2008-07-08 ПРИМЕНЕНИЕ 2-(1-ГИДРОКСИПЕНТИЛ)БЕНЗОАТ КАЛИЯ (dl-PHPB) ДЛЯ ПРЕДУПРЕЖДЕНИЯ И ЛЕЧЕНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА

Country Status (10)

Country Link
US (1) US20110224300A1 (ru)
EP (1) EP2332530B1 (ru)
JP (1) JP2011527290A (ru)
KR (1) KR20110039328A (ru)
AU (1) AU2008359085A1 (ru)
BR (1) BRPI0822492A2 (ru)
CA (1) CA2730154C (ru)
EA (1) EA022309B1 (ru)
IL (1) IL210525A0 (ru)
WO (1) WO2010003287A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103113210A (zh) * 2013-02-19 2013-05-22 石药集团中奇制药技术（石家庄）有限公司 羟戊基苯甲酸钾晶体及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1243541C (zh) * 2002-05-09 2006-03-01 中国医学科学院药物研究所 2－(α－羟基戊基)苯甲酸盐及其制法和用途
CN1565441B (zh) * 2003-06-20 2010-05-26 中国医学科学院药物研究所 左旋正丁基苯酞在制备预防或治疗痴呆的药物中的用途
US7078202B2 (en) * 2003-11-18 2006-07-18 Ultra Biotech Limited Methods and compositions for treating vascular dementia
CN100422134C (zh) * 2004-03-12 2008-10-01 北京天衡药物研究院 新的2-（α-正戊酮基）苯甲酸盐及其制法和用途
CN100435792C (zh) * 2004-04-23 2008-11-26 石药集团中奇制药技术（石家庄）有限公司 丁基苯酞类同系物在制备治疗抗血小板聚集和抗血栓药物中的应用
CN100540523C (zh) * 2004-06-17 2009-09-16 北京天衡药物研究院 L-2-（α-羟基戊基）苯甲酸盐及其制法和用途
CN101054346A (zh) * 2006-04-13 2007-10-17 温建波 一组新化合物及其组合物的制备方法和用途
US7824714B2 (en) * 2008-06-13 2010-11-02 Development Center For Biotechnology Chinese herb extract for treating dementia and preparation method thereof

Also Published As

Publication number Publication date
CA2730154A1 (en) 2010-01-14
CA2730154C (en) 2015-01-06
EP2332530A4 (en) 2012-02-01
EP2332530A1 (en) 2011-06-15
JP2011527290A (ja) 2011-10-27
US20110224300A1 (en) 2011-09-15
IL210525A0 (en) 2011-03-31
EP2332530B1 (en) 2014-10-08
BRPI0822492A2 (pt) 2015-06-16
WO2010003287A1 (zh) 2010-01-14
EA022309B1 (ru) 2015-12-30
AU2008359085A1 (en) 2010-01-14
KR20110039328A (ko) 2011-04-15

Similar Documents

Publication Publication Date Title
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
EA200701746A1 (ru) Фармацевтические композиции для лечения или профилактики заболеваний, в том числе ожирения, диабета, метаболического синдрома, нейродегенеративных заболеваний и заболеваний, связанных с нарушением деятельности митохондрий
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
WO2010057101A3 (en) Compounds useful as hiv blockers
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
MX2013008478A (es) 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2).
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
WO2009044392A3 (en) Novel sirna structures
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MA34147B1 (fr) Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
WO2007128086A3 (en) Novel viral replication inhibitor
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
AR068438A1 (es) Derivado de 6-pirimidinil-pirimid-2-ona
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
PH12015500012A1 (en) Benzodioxole derivative and preparation method and use thereof
AR068439A1 (es) Derivado de 6-pirimidinil-pirimid-2-ona
MX2010008690A (es) Farmacoforos duales - antagonistas muscarinicos de pde4.
ECSP088280A (es) Compuestos de imidazol para el tratamiento de trastornos neurológicos
MX2010008706A (es) Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU